Effect of carnitine-orotate complex on glucose metabolism and fatty liver: A double-blind, placebo-controlled study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 7, 2014, Pages 1449-1457

  Hong, Eun Shil ^a,b   Kim, Eun Ky ^a   Kang, Seon Mee ^b,c   Khang, Ah Reum ^a,b   Choi, Sung Hee ^a,b   Park, Kyong Soo ^a   Jang, Hak Chul ^a,b   Lim, Soo ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Sejong General Hospital   (South Korea)

Author keywords

Carnitine orotate; Fatty liver; Insulin resistance; Metformin; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AGENTS AFFECTING LIPID METABOLISM; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARNITINE DERIVATIVE; CARNITINE OROTATE COMPLEX; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GODEX; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MITOCHONDRIAL DNA; OROTIC ACID DERIVATIVE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARNITINE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; OROTIC ACID;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHROCYTE COUNT; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE DOSAGE; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; URINE VOLUME; ANALYSIS; BIOASSAY; COMPARATIVE STUDY; COPY NUMBER VARIATION; DRUG COMBINATION; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM DISORDERS; INSULIN RESISTANCE; MIDDLE AGED; PLACEBO EFFECT;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARNITINE; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDPOINT DETERMINATION; FASTING; FATTY LIVER; FEMALE; GLUCOSE METABOLISM DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; OROTIC ACID; OXIDATIVE STRESS; PLACEBO EFFECT;

EID: 84904311408     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12536     Document Type: Article

References (50)

1. Kral JG, Lundholm K, Bjorntorp P, Sjostrom L, Schersten T. Hepatic lipid metabolism in severe human obesity. Metabolism 1977; 26: 1025-1031.
2. Sanyal AJ, Campbell-Sargent C, Mirshahi F etal. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
3. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. 1983; 72: 1737-1747.
4. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2008; 19: 567-576.
5. Lutchman G, Modi A, Kleiner DE etal. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429.
6. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007; 8: 774-785.
7. Zhou G, Myers R, Li Y etal. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-1174.
8. Lavine JE, Schwimmer JB, Van Natta ML etal. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668.
9. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904.
10. Bugianesi E, Gentilcore E, Manini R etal. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005; 100: 1082-1090.
11. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 2004; 20: 23-28.
12. Haukeland JW, Konopski Z, Eggesbo HB etal. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol. 2009; 44: 853-860.
13. Murosaki S, Lee TR, Muroyama K etal. A combination of caffeine, arginine, soy isoflavones, and L-carnitine enhances both lipolysis and fatty acid oxidation in 3T3-L1 and HepG2 cells in vitro and in KK mice in vivo. J. Nutr. 2007; 137: 2252-2257.
14. Lin X, Shim K, Odle J. Carnitine palmitoyltransferase I control of acetogenesis, the major pathway of fatty acid {beta}-oxidation in liver of neonatal swine. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 298: R1435-R1443.
15. Westin MA, Hunt MC, Alexson SE. Short- and medium-chain carnitine acyltransferases and acyl-CoA thioesterases in mouse provide complementary systems for transport of beta-oxidation products out of peroxisomes. Cell. Mol. Life Sci. 2008; 65: 982-990.
16. Power RA, Hulver MW, Zhang JY etal. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007; 50: 824-832.
17. Noland RC, Koves TR, Seiler SE etal. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J. Biol. Chem. 2009; 284: 22840-22852.
18. Mynatt RL. Carnitine and type 2 diabetes. Diabetes Metab. Res. Rev. 2009; 25 (Suppl. 1): S45-S49.
19. Ringseis R, Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur. J. Nutr. 2012; 51: 1-18.
20. Rosenfeldt FL. Metabolic supplementation with orotic acid and magnesium orotate. Cardiovasc. Drugs Ther. 1998; 12 (Suppl. 2): 147-152.
21. Porto LC, de Castro CH, Savergnini SS etal. Improvement of the energy supply and contractile function in normal and ischemic rat hearts by dietary orotic acid. Life Sci. 2012; 90: 476-483.
22. Jun DW, Cho WK, Jun JH etal. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. Liver Int. 2011; 31: 1315-1324.
23. Lim CY, Jun DW, Jang SS, Cho WK, Chae JD, Jun JH. Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-alcoholic fatty liver disease. Korean J. Gastroenterol. 2010; 55: 384-389.
24. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 2009; 51: 433-445.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
26. Svoboda P, Ko SH, Cho B etal. Neopterin, a marker of immune response, and 8-hydroxy-2′-deoxyguanosine, a marker of oxidative stress, correlate at high age as determined by automated simultaneous high-performance liquid chromatography analysis of human urine. Anal. Biochem. 2008; 383: 236-242.
27. Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. Clin. Chem. 2002; 48: 1178-1185.
28. Nannipieri M, Gonzales C, Baldi S etal. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28: 1757-1762.
29. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
30. Tiikkainen M, Bergholm R, Vehkavaara S etal. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52: 701-707.
31. Vozarova B, Stefan N, Lindsay RS etal. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889-1895.
32. Cho NH, Jang HC, Choi SH etal. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care 2007; 30: 2566-2568.
33. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann. N. Y. Acad. Sci. 2004; 1033: 30-41.
34. Gulcin I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006; 78: 803-811.
35. Malaguarnera M, Gargante MP, Russo C etal. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis-a randomized and controlled clinical trial. Am. J. Gastroenterol. 2010; 105: 1338-1345.
36. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2009; 27: 120-139.
37. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr. Med. Chem. 2009; 16: 4654-4667.
38. Jung EJ, Kwon SW, Jung BH, Oh SH, Lee BH. Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. J. Lipid Res. 2011; 52: 1617-1625.
39. Wang YM, Hu XQ, Xue Y, Li ZJ, Yanagita T, Xue CH. Study on possible mechanism of orotic acid-induced fatty liver in rats. Nutrition 2011; 27: 571-575.
40. Durschlag RP, Robinson JL. Species specificity in the metabolic consequences of orotic acid consumption. J. Nutr. 1980; 110: 822-828.
41. Richards SM, Conyers RA, Fisher JL, Rosenfeldt FL. Cardioprotection by orotic acid: metabolism and mechanism of action. J. Mol. Cell. Cardiol. 1997; 29: 3239-3250.
42. Gasser T, Moyer JD, Handschumacher RE. Novel single-pass exchange of circulating uridine in rat liver. Science 1981; 213: 777-778.
43. Victor VM, Rocha M, Herance R, Hernandez-Mijares A. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr. Pharm. Des. 2011; 17: 3947-3958.
44. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
45. Petersen KF, Befroy D, Dufour S etal. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-1142.
46. Lim S, Kim SK, Park KS etal. Effect of exercise on the mitochondrial DNA content of peripheral blood in healthy women. Eur. J. Appl. Physiol. 2000; 82: 407-412.
47. Song J, Oh JY, Sung YA, Pak YK, Park KS, Lee HK. Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients. Diabetes Care 2001; 24: 865-869.
48. Lee HK, Song JH, Shin CS etal. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 1998; 42: 161-167.
49. Antonetti DA, Reynet C, Kahn CR. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with diabetes mellitus. J. Clin. Invest. 1995; 95: 1383-1388.
50. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005; 54: 1392-1399.